Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recuvyra
- Development stage
- Unknown
- Lead developer
- Elanco
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
Recuvyra is a high-concentration (50 mg/mL) transdermal solution of fentanyl, a small molecule mu-opioid receptor agonist, developed by Elanco for veterinary use in dogs. It is FDA-approved for the control of postoperative pain associated with orthopedic and soft tissue surgeries. The drug utilizes the patented Medistend transdermal delivery technology to establish a depot of fentanyl within the lipid layer of the stratum corneum, providing four days of continuous pain control from a single dose applied prior to surgery. Due to its high potential for abuse and human safety risks, Recuvyra is a Class II controlled substance and is distributed under a restricted Risk Minimization Action Plan (RiskMAP).
- Brand names
- Recuvyra
- Other names
- fentanyl transdermal solution
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Recuvyra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recuvyra.